ClinicalTrials.gg
CompletedNCT03713242Updated Jul 2, 2020

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

A Phase 1 interventional study of ACT-541468 25 mg and ACT-541468 25 mg (or 10 mg depending on interim results) in Hepatic Impairment, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-07-02.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2020, 6 years 8 months ago, and no results have been posted to the registry.
  • Registered 7 months after the study started (first participant enrolled Feb 2018, registered Oct 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of mild, moderate, and severe hepatic impairment due to liver cirrhosis on the pharmacokinetics of ACT-541468.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure.
  • Male and female subjects aged between 18 and 75 years (inclusive) at screening.
  • Women of must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use (from screening, during the entire study, and for at least one month after last study treatment intake) a highly effective method of , be sexually inactive, or have a vasectomized partner.
  • Women of non-childbearing potential.
  • of 18.0 to 35.0 kg/m2 (inclusive) at screening.
  • For healthy subjects: Normal renal function confirmed by a at screening according to Cockroft and Gault adjusted to age of:

    1. ≥ 80 mL/min/1.73 m2 for subjects ≤ 50 years of age.
    2. ≥ 70 mL/min/1.73 m2 for subjects 51-60 years of age.
    3. ≥ 60 mL/min/1.73 m2 for subjects 61-75 years of age.
  • For subjects with hepatic impairment: Degree of liver function impairment due to liver cirrhosis according to the classification:

    1. Group A: Mild hepatic impairment, Child-Pugh score 5-6.
    2. Group B: Moderate hepatic impairment, Child-Pugh score 7-9.
    3. Group C: Severe hepatic impairment, Child-Pugh score 10-15.

Exclusion criteria

Exclusion Criteria:

  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • For subjects with hepatic impairment: History of major medical or surgical disorders, which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment except for those related to liver cirrhosis (appendectomy and herniotomy allowed, cholecystectomy not allowed).
  • For healthy subjects:

    1. History of alcoholism or drug abuse within the 3-year period prior to screening.
    2. Relevant history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Group A: ACT-541468 in subjects with mild hepatic impairment

    Single oral dose administered on Day 1.

    Drug: ACT-541468 25 mg

  • Experimental
    Group B: ACT-541468 in subj. with moderate hepatic impairment

    Single oral dose administered on Day 1.

    Drug: ACT-541468 25 mg (or 10 mg depending on interim results)

  • Experimental
    Group C: ACT-541468 in subjects with severe hepatic impairment

    Single oral dose administered on Day 1.

    Drug: ACT-541468 25 mg (or 10 mg depending on interim results)

  • Experimental
    Group D: ACT-541468 in healthy subjects.

    Single oral dose administered on Day 1.

    Drug: ACT-541468 25 mg (or 10 mg depending on interim results)

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events (AEs)

    Time frame: From study treatment administration up to EOS (duration: up to 4 days)

  2. Treatment-emergent serious adverse events (SAEs)

    Time frame: From study treatment administration up to EOS (duration: up to 4 days)

Other outcomes

  1. Plasma pharmacokinetics: AUC(0-t)

    Time frame: At various timepoints (duration: up to 4 days)

  2. Plasma pharmacokinetics: AUC(0-inf)

    Time frame: At various timepoints (duration: up to 4 days)

  3. Plasma pharmacokinetics: AUC(0-24)

    Time frame: At various timepoints (duration: up to 4 days)

  4. Plasma pharmacokinetics: Cmax

    Time frame: At various timepoints (duration: up to 4 days)

  5. Plasma pharmacokinetics: Tmax

    Time frame: At various timepoints (duration: up to 4 days)

  6. Plasma pharmacokinetics: T1/2

    Time frame: At various timepoints (duration: up to 4 days)

  7. Plasma pharmacokinetics: Cu/C (extent of plasma protein binding)

    Time frame: At various timepoints (duration: up to 4 days)

07

Study locations

1 site
  • University Hospital Basel
    Basel, 4031, Switzerland
08

References and documents

Publications

  • Berger B, Dingemanse J, Sabattini G, Delahaye S, Duthaler U, Muehlan C, Krahenbuhl S. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clin Pharmacokinet. 2021 Oct;60(10):1349-1360. doi: 10.1007/s40262-021-01028-8. Epub 2021 May 18. PubMed 34002356 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Feb 2020, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2018
First posted
Oct 19, 2018
StartActual
Feb 26, 2018
Primary completionActual
Feb 27, 2020
CompletionActual
Feb 27, 2020
Last update
Jul 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03713242
Responsible party
Sponsor
First posted
Oct 19, 2018
Start date
Feb 26, 2018
Primary completion
Feb 27, 2020
Completion
Feb 27, 2020
Last update
Jul 2, 2020

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion